Table 3.
Characteristics of simulation models on biennial FIT screening from the age of 55 to 75.
| Model | Study No. | Study | Simulate Population | Screening Age | Simulation Period/Follow-Up Time (Years) | Adherence Rate in Screening Group (%) | CRC Mortality of No Screening Group | CRC Mortality of Screening Group |
|---|---|---|---|---|---|---|---|---|
| ASCCA | 1 | Bronzwaer, M. E. S. (2018) [19] | Dutch | 55–75 | 2014–2044 | 73% (FIT)/92% (FIT-positive CS) | 42.3/100,000 | 20.4/100,000 |
| 2 | Greuter, M. J. (2016) [26] | Dutch | 55–75 | 2014–2044 (30 years) | 63% (FIT)/82% (FIT-positive CS) | 44.0/100,000 | 21.0/100,000 | |
| 3 | Greuter, M. J. (2016) [27] | Dutch | 55–75 | Lifetime (11 rounds) | 63% (FIT)/96% (FIT-positive CS) | 28.3/1000 | 12.2/1000 | |
| 4 | Greuter, M. J. (2016) [28] | Dutch | 55–75 | 2014–2044 (30 years) | 63% (FIT)/96% (FIT-positive CS) | 44.0/100,000 | 23.3/100,000 | |
| 5 | Greuter, M. J. E. (2017) [12] | Dutch | 55–75 | Lifetime | 72.6% (FIT)/92% (FIT-positive and Surveillance CS) | 28.2/1000 | 13.5/1000 | |
| 6 | Vleugels, J. L. A. (2017) [43] | Dutch | 55–75 | Lifetime | 73% (FIT)/92% (FIT-positive CS) | 28.2/1000 | 14.0/1000 | |
| CRC-AIM | 7 | Piscitello, A. (2020) [40] | US | 55–75 | Lifetime | 100% | 31.7/1000 | 12.0/1000 |
| SimCRC | 8 | Knudsen, A. B. (2016) [31] | US | 55–75 | Lifetime | 100% | 28.0/1000 | 9.0/1000 |
| 9 | Knudsen, A. B. (2021) [30] | US | 55–75 | Lifetime | 100% | 34.0/1000 | 12.0/1000 | |
| 10 | Meester, R. G. S. (2018) [36] | US White Female | 55–75 | Lifetime | 100% | 25.7/1000 | 8.7/1000 | |
| US Black Female | 55–75 | Lifetime | 100% | 30.0/1000 | 12.0/1000 | |||
| US White Male | 55–75 | Lifetime | 100% | 31.0/1000 | 10.0/1000 | |||
| US Black Male | 55–75 | Lifetime | 100% | 27.0/1000 | 10.0/1000 | |||
| CRC-SPIN | 8 | Knudsen, A. B. (2016) [31] | US | 55–75 | Lifetime | 100% | 27.0/1000 | 10.0/1000 |
| 9 | Knudsen, A. B. (2021) [30] | US | 55–75 | Lifetime | 100% | 32.0/1000 | 12.0/1000 | |
| MISCAN-Colon | 8 | Knudsen, A. B. (2016) [31] | US | 55–75 | Lifetime | 100% | 28.0/1000 | 11.0/1000 |
| 9 | Knudsen, A. B. (2021) [30] | US | 55–75 | Lifetime | 100% | 34.0/1000 | 15.0/1000 | |
| 10 | Meester, R. G. S. (2018) [36] | US White Female | 55–75 | Lifetime | 100% | 21.9/1000 | 9.9/1000 | |
| US Black Female | 55–75 | Lifetime | 100% | 28.4/1000 | 12.4/1000 | |||
| US White Male | 55–75 | Lifetime | 100% | 27.2/1000 | 11.2/1000 | |||
| US Black Male | 55–75 | Lifetime | 100% | 29.6/1000 | 12.6/1000 | |||
| 11 | Cenin, D. R. (2020) [22] | Australian | 54–74 | Lifetime 40–100 | 100% | 29.0/1000 | 16.0/1000 | |
| Australian | 54–74 | Lifetime 40–100 | Realistic adherence | 29.0/1000 | 22.0/1000 | |||
| 12 | Gini, A. (2021) [62] | Dutch | 55–75 | 2018–2050 | 71.3% | 26.5/1000 | 19.5/1000 | |
| 13 | Cenin, D. (2022) [60] | Chinese | 55–75 | Lifetime | 100% | 11.0/1000 | 5.0/1000 | |
| 14 | Buskermolen, M. (2022) [59] | Dutch | 55–75 | Lifetime | 72.4% | 37.3/1000 | 10.1/1000 | |
| 15 | Heinävaara, S. (2022) [63] | Finnish | 55–74 | Lifetime | 100% | 23.0/1000 | 14.0/1000 |